-
Mashup Score: 0Personalized Diabetes Prevention: Insights from 15 Years of the VA MOVE! Program, with Qiaochu Xue, PhD, MPH - 13 day(s) ago
Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.
Source: www.hcplive.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
CagriSema shows weight loss results in recent trials comparable to existing interventions.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
CagriSema combination therapy was associated with weight reductions in the highest range of existing weight loss interventions in new data from #ADASciSessions. https://t.co/TqX8WeXNOA
-
-
Mashup Score: 0
A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Universal semaglutide access could reduce all-cause mortality by 7.41%, saving 28 million lives over five years. #ADASciSessions https://t.co/u0C7G4BRpd
-
-
Mashup Score: 0
Steger discussed findings from a 6-month lifestyle investigating TRE+ER and IER.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Felicia Steger, PhD, RD,@UnivOfKansas discussed an intermittent fasting intervention that led to clinical improvements in people with type.2 #diabetes at #ADASciSessions. Watch now: https://t.co/lNM6PKzj1J
-
-
Mashup Score: 0
A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes, simplifying insulin therapy and enhancing patient adherence.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
For people with #Type2Diabetes starting insulin therapy, a once-weekly insulin named efsitora alfa is just as effective in lowering blood glucose as a daily regimen with daily basal #insulin, according to a new study. https://t.co/5s93Kb45DX #ADASciSessions
-
-
Mashup Score: 0
Kevin Sayer joins the program to discuss the latest from Dexcom and preview where the business is headed in an evolving diabetes landscape.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Kevin Sayer joins #DiabetesDialogue to discuss the latest from @dexcom and preview where the business is headed in an evolving diabetes landscape. Watch now: https://t.co/hmHY2oUzDR
-
-
Mashup Score: 0Once-Weekly Insulin Efsitora a Practical Option for Type 2 Diabetes, with Athena Philis-Tsimikas, MD - 13 day(s) ago
Philis-Tsimikas shared the latest findings demonstrating inferiority after switching from daily basal insulin to weekly insulin efsitora.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
"[Weekly insulin] might be a learning curve, but knowing that the patients overall really like this and it leads to good outcomes for their glucose control, make it worthwhile in the long run." - Athena Philis-Tsimikas, MD @ScrippsHealth #ADASciSessions https://t.co/67sQmREanT
-
-
Mashup Score: 1Diabetes Dialogue: REDFINE 1 and REDEFINE 2, with Timothy Garvey, MD, and Melanie Davies, MD - 13 day(s) ago
Explore groundbreaking findings from the REDEFINE trials on CagriSema’s impact on weight loss and diabetes management at ADA 2025.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
🚨Special edition #DiabetesDialogue is hot off the presses from #ADASciSessions! Dive into the REDEFINE 1 and REDEFINE 2 trials of CagriSema + Semaglutide for weight loss now with investigators W. Timothy Garvey, MD, and Melanie Davies, MD now: https://t.co/JN6qjk9ZMi
-
-
Mashup Score: 3
New research reveals amycretin’s promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
New research reveals amycretin's promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options. https://t.co/v3J2w7IG2N #ADA2025 #Diabetes #Obesity
-
-
Mashup Score: 3Diabetes Dialogue: REDFINE 1 and REDEFINE 2, with Timothy Garvey, MD, and Melanie Davies, MD - 14 day(s) ago
Explore groundbreaking findings from the REDEFINE trials on CagriSema’s impact on weight loss and diabetes management at ADA 2025.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Explore groundbreaking findings from the REDEFINE trials on CagriSema's impact on weight loss and diabetes management at #ADA2025 in the latest #DiabetesDialogue: https://t.co/nC7omta0ug #ADASciSessions #Obesity https://t.co/ZU0eYcnwqk
-
Qiaochu Xue, PhD, discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention at #ADASciSessions. Read more: https://t.co/xkl2strG0H